- Home
- MLTX vs PGEN Comparison
MLTX vs PGEN Comparison
Compare MLTX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLTX
- PGEN
- Stock Information
- Founded
- MLTX 2021
- PGEN 1998
- Country
- MLTX Switzerland
- PGEN United States
- Employees
- MLTX N/A
- PGEN N/A
- Industry
- MLTX Biotechnology: Pharmaceutical Preparations
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- MLTX Health Care
- PGEN Health Care
- Exchange
- MLTX Nasdaq
- PGEN Nasdaq
- Market Cap
- MLTX 535.3M
- PGEN 493.0M
- IPO Year
- MLTX N/A
- PGEN N/A
- Fundamental
- Price
- MLTX $9.40
- PGEN $3.28
- Analyst Decision
- MLTX Buy
- PGEN Buy
- Analyst Count
- MLTX 9
- PGEN 5
- Target Price
- MLTX $37.63
- PGEN $7.50
- AVG Volume (30 Days)
- MLTX 9.7M
- PGEN 5.8M
- Earning Date
- MLTX 11-06-2025
- PGEN 11-13-2025
- Dividend Yield
- MLTX N/A
- PGEN N/A
- EPS Growth
- MLTX N/A
- PGEN N/A
- EPS
- MLTX N/A
- PGEN N/A
- Revenue
- MLTX N/A
- PGEN $4,340,000.00
- Revenue This Year
- MLTX N/A
- PGEN $249.10
- Revenue Next Year
- MLTX N/A
- PGEN $710.03
- P/E Ratio
- MLTX N/A
- PGEN N/A
- Revenue Growth
- MLTX N/A
- PGEN N/A
- 52 Week Low
- MLTX $5.95
- PGEN $0.65
- 52 Week High
- MLTX $62.75
- PGEN $5.23
- Technical
- Relative Strength Index (RSI)
- MLTX 23.29
- PGEN 46.00
- Support Level
- MLTX $6.56
- PGEN $3.37
- Resistance Level
- MLTX $7.48
- PGEN $4.00
- Average True Range (ATR)
- MLTX 2.22
- PGEN 0.25
- MACD
- MLTX -4.37
- PGEN -0.12
- Stochastic Oscillator
- MLTX 6.07
- PGEN 21.08
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.